A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and

2 Disease

1

- 3 Oriol Mitjà PhD, 1,2,3 Maria Ubals BM, Marc Corbacho-Monné BM, Andrea Alemany BM, Clara
- 4 Suñer PhD, ¹ Cristian Tebe PhD, ⁴ Aurelio Tobias PhD, ⁵ Judith Peñafiel MSc, ⁴ Ester Ballana PhD, ⁶, ¹
- 5 Carla A. Pérez BM, ¹ Pol Admella BM, ¹ Nuria Riera-Martí BM, ¹ Pep Laporte BM, ¹ Jordi Mitja MBA, ¹
- 6 Mireia Clua MBA, ¹ Laia Bertran MA, ¹ Maria Sarquella MA, ¹ Sergi Gavilán BA [Jordi Ara PhD, ² Josep
- 7 M Argimon PhD, Gabriel Cuatrecasas BM, Paz Cañadas PhD, Aleix Elizalde-Torrent PhD, Robert
- 8 Fabregat PhD, 10 Magí Farré PhD, 2 Anna Forcada BM, 11 Gemma Flores-Mateo PhD, 12 Cristina López
- 9 BSc, ¹³ Esteve Muntada MSc, ¹⁴ Núria Nadal MB, ¹⁵ Silvia Narejos BM, ¹⁶ Aroa N Gil-Ortega BN, ¹ Nuria
- 10 Prat BM, ¹⁷ Jordi Puig BN, ¹ Carles Quiñones MPharm, ² Ferran Ramírez-Viaplana MSc, ¹ Juliana Reyes-
- 11 Urueña PhD, ¹⁴ Eva Riveira-Muñoz PhD, ⁶ Lidia Ruiz PhD, ⁶ Sergi Sanz PhD, ¹⁸ Alexis Sentis MB, ¹⁴ Alba
- 12 Sierra BN, ¹ César Velasco PhD, ¹⁹ Rosa Maria Vivanco-Hidalgo PhD, ¹⁹ Juani Zamora BSc¹³, on behalf of
- the BCN PEP-COV RESEARCH GROUP], Jordi Casabona MPH, 7,20 Martí Vall-Mayans PhD, 1,2 Camila
- 14 G-Beiras PhD, 1‡ Bonaventura Clotet PhD 1, 2, 21‡
- 16 *‡ Both authors contributed equally
- 17 1. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
- 18 2. Hospital Universitari Germans Trias i Pujol, Badalona Spain
- 19 3. Lihir Medical Centre-International SOS, Lihir Island, Papua New Guinea
- 20 4. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
- 21 5. Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific
- 22 Research (CSIC), Barcelona, Spain
- 23 6. IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
- 7. Direcció-gerència, Institut Català de la Salut, Barcelona, Spain
- 8. Equip d'atenció primària de Sarria, Barcelona, Spain
- 9. SYNLAB, Barcelona, Spain
- 27 10.Direcció General de Recerca i Innovació en Salut, Generalitat de Catalunya, Barcelona, Spain
- 28 11. Gerència territorial de Catalunya Central, Institut Català de la Salut, St. Fruitós de Bages, Spain
- 29 12. Xarxa Santa Tecla Sanitària i Social. Tarragona, Spain
- 30 13. TFS Clinical Contract Research Organization, Barcelona, Spain
- 31 14. Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Catalan Institute
- 32 of Oncology (ICO)-Departament de Salut, Generalitat de Catalunya, Badalona, Spain
- 33 15. Gerència territorial de Barcelona, Institut Català de la Salut, Barcelona, Spain

34 16. Entitat de Base Asociativa Centelles- Atenció Primària, Centelles, Spain 17. Gerència territorial de Àmbit Metropolità nord, Institut Català de la Salut, Sabadell, Spain 35 36 18. ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. 37 19. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, Spain 38 20. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, 39 Spain 40 21. Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain 41 42 43 44 Corresponding author: Oriol Mitjà, omitja@flsida.org, Hospital Germans Trias i Pujol, Carretera Canyet 45 s/n, 08916, Badalona, Spain

ABSTRACT

49 Background

48

- 50 Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- 51 infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been
- 52 proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive
- evidence is lacking.
- 54 Methods
- We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a
- 56 PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy
- 57 (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary
- outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-
- 59 CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms.
- Adverse events (AEs) were assessed up to 28 days.
- 61 Results
- 62 The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and
- 63 Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There
- was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease
- 65 (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of
- beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The
- 67 incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6%
- 68 HCQ), but no treatment-related serious AEs were reported.
- 69 Conclusions

7374

- 70 Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy
- 71 individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure
- 72 prophylaxis for Covid-19.
 - ClinicalTrials.gov registration number: NCT04304053

INTRODUCTION

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

Coronavirus 2019 disease (Covid-19) is a rapidly emerging infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rate of new cases among contacts (secondary attack rate) has been estimated as 10 to 15%. 1-4 The current infection control strategy is based on social distancing and isolation of cases and contacts.⁵ The effectiveness of the latter depends on the promptness of the intervention, level of contact tracing, and level of isolation compliance. Unfortunately, real-world constraints for implementing full effective measures have resulted in SARS-CoV-2 spread in many countries. Postexposure prophylaxis of healthy contacts is among the measures used for outbreak control of several infectious diseases, for example, in pandemic influenza. No agent is known to be effective in preventing SARS-CoV-2 infection or disease, but several drugs have shown antiviral activity in the laboratory, including the aminoquinolines hydroxychloroquine (HCQ) and chloroquine.⁸ In-vitro results showed that these drugs block the SARS-CoV-2 viral spread in cell cultures⁹⁻¹¹ and that HCQ was more effective at impairing SARS-CoV-2 viral replication compared to chloroquine. ¹¹ To date, only one RCT has reported on HCQ for postexposure prophylaxis for Covid-19. 12 However, concerns have been raised about the trial design, primarily because most participants were diagnosed with an influenza-like illness based on symptoms alone, and only 20% of their Covid-19 outcome was confirmed with PCR. We investigated the efficacy and safety of HCQ to prevent secondary PCR-confirmed symptomatic Covid-19 (confirmed Covid-19) and SARS-CoV-2 infection in contacts exposed to a PCR-positive Covid-19 case during the outbreak in Catalonia, the region with the second highest number of Covid-19 cases in Spain.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

5

Following a similar approach as the ring vaccination trial "Ebola Ça Suffit!", 14 we defined study clusters

(called rings) of healthy individuals (contacts) epidemiologically linked to a PCR-positive Covid-19 case

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

7

visit and laboratory methods for SARS-CoV-2 identification and quantification (Fig. S2) are provided in the Supplementary Appendix. **OUTCOMES** The primary outcome was the onset of a confirmed Covid-19 episode, defined as symptomatic illness (at least one of the following symptoms: fever, cough, difficulty breathing, myalgia, headache, sore throat, new olfactory and taste disorder(s), or diarrhea) and a positive SARS-CoV-2 RT-PCR test. The primary outcome was assessed in all asymptomatic individuals, irrespective of the PCR result; in a post hoc analysis, we explored the outcome in individuals with positive and negative PCR separately. Time-toevent was defined as the number of days from the date of randomization/exposure to the confirmed date of the onset of symptomatic illness. The secondary outcome was the incidence of SARS-CoV-2 infection, defined as either the RT-PCR detection of SARS-CoV-2 in a nasopharyngeal specimen or the presence of any of the aforementioned symptoms compatible with Covid-19. The rationale for this outcome was to encompass definitions of Covid-19 used elsewhere 12,15 and all possible viral dynamics. We, therefore, assumed that if clinical suspicion is high, infection should not be ruled out based on a negative PCR alone—particularly early in the course of infection. 15 Participants who were hospitalized or died and whose hospital/vital records listed Covid-19 as the main diagnosis (including PCR confirmation) were also considered for the primary and secondary outcomes. We also measured serological positivity (IgM/IgG) of contacts at day 14. Safety outcomes included the frequency and severity of adverse events (AE), serious AE (SAE), and AE of special interest (e.g., cardiac) up to 28 days from treatment start. Causality was assessed by an external panel of pharmacovigilance consultants. STATISTICAL ANALYSIS With an enrollment target of 95 clusters per trial group 16 —15 participants per cluster and intraclass

correlation of 1.0— the initial design yielded 90% power to detect a difference of 10% in the incidence,

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

with expected incidence of 15% in the control arm. Owing to the limited information available by March 2020 regarding the cluster size and the incidence of Covid-19 after exposure, the protocol prespecified a sample-size re-estimation at the interim analysis. This re-estimation was aimed at maintaining the ability (80% power) to detect a reduction from 6.5% to 3% of the primary outcome, yielding 320 clusters per trial group with 3.5 participants per cluster. The primary efficacy analysis was performed on the intention-to-treat (ITT) population, which included all randomized subjects with complete outcome data. We decided not to impute outcome data to participants with missing measurements because this approach would have biased the incidence of secondary Covid-19 events. Sensitivity analyses were performed with the per-protocol (PP) population in participants who completed the trial according to the protocol. The safety population included all participants who received any trial intervention, including usual care. The cumulative incidence in primary, secondary, and safety outcomes was compared at the individual level using a binomial regression model with robust sandwich standard errors to account for clustering within rings.¹⁷ We defined a generalized linear model with a binomial distribution and a logarithm link function to estimate the relative risk (RR) as a measure of effect. 18 The individual-level variables we adjusted for are age, gender, region, and time of exposure. We did additional pre-specified analyses to assess the consistency of treatment effects in subgroups defined according to the viral load of the contact at baseline, viral load of the index case, place of exposure, time of exposure to the index case. Survival curves by study groups on time-to-event outcomes were compared using a Cox proportional hazards model with a cluster-level frailty term to adjust for clustering. ¹⁹ The significance threshold was set at a two-sided alpha value of 0.05, unless otherwise indicated, and all statistical analyses were conducted in R version 3.6.2.²⁰

RESULTS

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

CHARACTERISTICS OF STUDY PARTICIPANTS Between Mar 17 and Apr 28, 2020, we assessed 754 Covid-19 index cases for eligibility; 672 of them were selected for defining the corresponding clusters, which included 4,399 contacts (Fig. 1), 1,874 (42.6%) of the 4,399 contacts were not enrolled because of at least one exclusion criteria, including contacts presenting Covid-19-like symptoms before enrolment (n = 537). Additionally, 211 (8.4%) of 2.525 enrolled contacts were excluded from ITT analysis because of screening failure or missing PCR results on day 14, yielding an ITT population of 2,314 contacts. During follow-up, 64 participants had a protocol deviation regarding the intervention (PP population of 2,250 contacts). The demographic, clinical, and epidemiological characteristics of participants at baseline were similar in the two study arms (Table 1, PP analysis in the Supplementary Appendix). The mean age of contacts was 48.6 years (SD 19.0) and the PCR test at baseline was negative in 87.8% of them (2,000 of 2,314). Overall, 55.6% of the participants (1,287 of 2,314) reported chronic health conditions. The median length from exposure to enrolment was 4.0 (IQR 3.0-6.0) days. The size of clusters was similar in both arms (median 2.0 vs. 2.0; P = 0.25). Exposure was predominantly from an index case with moderate-to-high viral load shedding (460 of 549 [83.8%] index cases with available viral load assessment). Health care workers and nursing home workers accounted for 60.3% (1,395) of the participants; 27.7% (640) were enrolled as household contacts, and 12.7% (293) as nursing home residents. Overall, 67.2% (1,555) of participants reported routine use of masks at the time of exposure, and 6.2% (144) of contacts continued to sleep in the same room as the index case. PRIMARY OUTCOME During the 14-day follow-up, 138 (6.0%) of 2,314 participants experienced a PCR-confirmed, symptomatic Covid-19 episode. The primary outcome was similar in the control arm (6.2%; 74/1,198)

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

participants who became PCR-positive during follow-up, 30 (24.0%) were seropositive on day 14 (Fig S4).

ADHERENCE AND SAFETY

Full adherence for the trial intervention was 97.5% (1,268 of 1,300) in the control arm and 95.1% (1,138 of 1,1197) in the intervention arm. In the safety population, 77/1,300 (5.9%) participants in the control arm and 671/1,197 (51.6%) in the intervention arm experienced at least one AE during 14 days of follow-up (Table 3). The most frequent treatment-related AEs among participants given HCQ were gastrointestinal (diarrhea, nausea, and abdominal pain) and nervous system disorders (drowsiness, headache, and metallic taste) (Tables S4). Thirty-one SAE were reported, 17 in the control arm and 14 in the intervention arm, none of them related to HCQ (Table S5). Six AEs of special interest were observed, including five episodes of self-limited palpitations potentially related to treatment (Table S6). Relevant safety data listings are provided in the Supplementary Appendix.

DISCUSSION

Postexposure prophylaxis with HCQ did not prevent Covid-19 disease or SARS-CoV-2 infection in asymptomatic contacts exposed to a PCR-positive index case. In our cohort, the overall attack rate for the PCR-confirmed symptomatic Covid-19 was 6.0%, excluding subjects that were not enrolled because had symptoms before the baseline assessment. HCQ did not decrease the incidence of confirmed Covid-19 disease among contacts (6.2 vs. 5.7%). Our trial tested two possible effects of postexposure therapy: prophylaxis in contacts with negative PCR at baseline, and preemptive therapy in contacts with positive PCR at baseline (i.e., prevent progression of asymptomatic infection to disease). This dual scenario mirrors a real-life setting, where the PCR result of people exposed to a known Covid-19 case is usually not available immediately. Among PCR positive contacts at baseline (12% of subjects), the intervention had no apparent efficacy as early preemptive therapy. Of note a baseline positive PCR result significantly

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

12

reported in the control, non-placebo group), but it did not affect the attrition numbers in the control arm.

However, it is worth mentioning that the laboratory staff who performed PCR tests remained unaware of the allocation of each sample. Despite the promising in-vitro results that placed HCQ among the leading candidates for Covid-19 treatment and prophylaxis, ^{23–25} to date there is no strong argument to suggest that HCQ is effective. We provide high-quality evidence on the lack of efficacy of postexposure prophylaxis therapy with HCQ to prevent Covid-19 disease or SARS-CoV-2 infection. The data presented in this report is particularly valuable for the scientific community and policymakers involved in controlling the pandemic at the population level. Our findings encourage directing efforts to other antiviral candidates for postexposure prophylaxis. **CONTRIBUTORS** OM, LB, BC, CV, RMV, JC, CGB, MVM conceived, designed and wrote the manuscript,

- 296
- MU, AA, CS, MC, PA, CA, AET, PL, SN, AN, JP, CQ, FMV, NRM, AS, CS, GFM, AF, GC, NP, NN 297
- 298 contributed to the recruitment, clinical care, and follow-up of patients,
- 299 CT, AT, CL, EM, JP JR, AS, JZ, EM, JRU, SS analyzed and managed data
- 300 JA, JMA, JC, RF, MF analyzed data and reviewed the manuscript
- 301 EB, PC, ERM, LR Did all laboratory tests
- 302 JM, MC, MS, SG directed and managed the planning and execution of the project
- All authors reviewed and approved the final version of the manuscript 303

FUNDING

- 306 Crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), Laboratorios Rubió,
- 307 Laboratorios Gebro Pharma, Zurich Seguros, SYNLAB Barcelona, and Generalitat de Catalunya.
- 308 Laboratorios Rubió also contributed to the study with the required doses of hydroxychloroguine
- 309 (Dolquine®).

286

287

288

289

290

291

292

293

294

295

304

CONFLICTS OF INTEREST

We declare no conflicts of interest

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

ACKNOWLEDGMENTS

This study was mainly supported by the crowdfunding campaign **JoEmCorono** (https://www.yomecorono.com/) with the contribution of over 72,000 citizens and corporations. The study also received financial support from Laboratorios Rubió, Gebro Pharma, Zurich Seguros, SYNLAB Barcelona, and Generalitat de Catalunya. Laboratorios Rubió also contributed to the study with the required doses of hydroxychloroquine (Dolquine®). We thank Gerard Carot-Sans, PhD, for providing medical writing support during the revisions of the subsequent manuscript drafts, Eric Ubals (Pierce AB) and Oscar Palao (Opentic) for website and database management, Óscar Camps and OpenArms Non-governtmental organization for nursing home operations, Anna Valentí and the human resources department of the Hospital Germans Trias i Pujol for telephone monitoring. We are very grateful to Marc Clotet and Natalia Sánchez who coordinated the JoEmCorono crowdfunding campaign. We thank the institutional review board of Hospital Germans Trias Pujol and the Spanish Agency of Medicines and Medical Devices (AEMPS) for their prompt action for consideration and approvals to the protocol.

REFERENCES

330

350

351

331 1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel 332 Coronavirus–Infected Pneumonia. N Engl J Med 2020;382:1199–207. 333 2. Bi O, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of 334 their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 335 2020;doi.org/10.1016/S1473-3099(20)30287-5. 336 World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 3. 337 2019 (COVID-19) [Internet]. 2020 [cited 2020 Mar 29];Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-338 339 report.pdf 340 4. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase 341 342 of the outbreak. Int J Infect Dis 2020;92:214–7. 343 5. World Health Organization (WHO). Strengthening Preparedness for COVID-19 in Cities and 344 Urban Settings [Internet]. COVID-19 Crit. Prep. readiness response. 2020 [cited 2020 May 345 25];Available from: https://www.who.int/publications-detail/strengthening-preparedness-for-346 covid-19-in-cities-and-urban-settings 347 Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation 6. 348 of cases and contacts. Lancet Glob Heal 2020;8(4):e488–96. 349 7. World Health Organization. WHO global influenza preparedness plan: The role of WHO and

recommendations for national measures before and during pandemics [Internet]. 2005 [cited 2020]

Mar 29]; Available from: https://apps.who.int/iris/handle/10665/68998

- 8. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug
- 353 Discov Ther 2020;14(1):58–60.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently
- emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269–71.
- 356 10. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS
- 357 coronavirus infection and spread. Virol J 2005;2(1):1–10.
- 358 11. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing
- Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome
- 360 Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;ciaa237.
- 361 12. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as
- Postexposure Prophylaxis for Covid-19. N Engl J Med 2020;1–9.
- 363 13. Catalan Ministry of Health. Catalan epidemiological surveillance system [Internet]. [cited 2020
- Mar 28]; Available from: http://salutpublica.gencat.cat/ca/ambits/vigilancia_salut_publica/
- 365 14. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-
- vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination,
- open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 2017;389(10068):505–18.
- 368 15. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of
- Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since
- 370 Exposure. Ann Intern Med 2020;doi.org/10.7326/M20-1495.
- 371 16. Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of
- variation of cluster size and analysis method. Int J Epidemiol 2006;35(5):1292–300.

- 373 17. Campbell MJ, Donner A, Klar N. Developments in cluster randomized trials and statistics in
- 374 medicine. Stat Med 2007;26(1):2–19.
- 375 18. Wacholder S. Binomial regression in glim: Estimating risk ratios and risk differences. Am J
- 376 Epidemiol 1986;123(1):174–84.
- 377 19. O'Quigley J, Stare J. Proportional hazards models with frailties and random effects. Stat Med
- 378 2002;21(21):3219–33.
- 379 20. R Core Team. R: A language and environment for statistical com puting [Internet]. R Found.
- Stat. Comput. Vienna, Austria. 2017 [cited 2020 May 25]; Available from: https://www.r-
- 381 project.org
- 382 21. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic
- 383 SARS-CoV-2 infections. Nat Med 2020;1–5.
- 384 22. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated with Use of
- 385 Hydroxychloroquine with or without Concomitant Azithromycin among Hospitalized Patients
- 386 Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol
- 387 2020;10.1001/jamacardio.2020.1834.
- 388 23. Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising
- 389 coronavirus treatments. Science (80-) 2020;10.1126/science.abb8497.
- 390 24. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective
- in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6(1):1–4.
- 392 25. Pastick KA, Okafor EC, Wang F, et al. Hydroxychloroquine and Chloroquine for Treatment of
- 393 SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020;2:1–9.

395 396 397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

18

Figure legends Figure 1. Flow diagram of individual selection and allocation. Legend. The safety population (n=2,497; 1,300 in the control arm and 1,197 in the intervention arm) included all individuals in the ITT population (except 28 not receiving any dose of study medication) plus 211 participants that received medication but were excluded from ITT because of screening-failure, or missing PCR results on Day 14. Figure 2. Association of baseline viral load of participants and viral load of their index case with breakthrough Covid-19 (ITT population) Legend. Panels A and B show the association of the participant's viral load at baseline (A) and viral load of the index case (B) with the likelihood of developing PCR-confirmed symptomatic Covid-19 in the overall intention-to-treat population (aggregated data for the control and intervention arms). The dots are participants with (=1) or without (=0) the primary outcome of PCR-confirmed Covid-19. Panel C shows the viral load increase from baseline in participants who developed or did not develop Covid-19 (details are provided in Table S2, Supplementary Appendix). Figure 3. Subgroup analyses for the primary outcome according to risk of exposure factors (ITT population)

Tables

Table 1. Baseline characteristics of study participants (contacts) included in the intention-to-treat population (N=2314).

	Control	Intervention	
	arm	arm	
Individuals' characteristics	(N=1,198)	(N=1,116)	
	40.7 (10.2)	40 € (10.7)	
Age (years), mean (SD)	48.7 (19.3)	48.6 (18.7)	
Gender (female), n (%)	875 (73.0%)	813 (72.8%)	
PCR result at baseline, n (%) (N=2279) *	1015 (00 5)		
Undetectable (< 10 ⁴ copies/mL)	1042 (88.5%)	958 (86.9%)	
10^4 - 10^6 copies/mL	88 (7.5%)	78 (7.1%)	
$10^7 - 10^9$ copies/mL	42 (3.6%)	58 (5.3%)	
10^{10} - 10^{12} copies/mL	5 (0.4%)	8 (0.7%)	
Coexisting disease			
None	547 (45.7%)	480 (43.0%)	
Cardiovascular disease	178 (14.9%)	130 (11.6%)	
Respiratory disease	47 (3.9%)	64 (5.7%)	
Metabolic disease	94 (7.8%)	99 (8.9%)	
Nervous system disease	170 (14.2%)	170 (15.2%)	
Characteristics of clusters			
Number of days of exposure before enrollment, median (IQR)	4.0 (3.0, 6.0)	4.0 (3.0, 6.0)	
Number of days of exposure before the intervention, N (%)			
≤3 days	411 (34.3%)	440 (39.4%)	
4-6 days	668 (55.8%)	551 (49.3%)	
≥7 days	119 (9.9%)	125 (11.2%)	
Size of clusters, <i>median (IQR)</i>	2.0 (1.0, 3.0)	2.0 (1.0, 3.0)	
Viral load of the index case, n (%) (N=549)	, , ,	, , ,	
Undetectable (< 10 ⁴ copies/mL) †	47 (16.2%)	42 (16.2%)	
10^4 - 10^6 copies/mL	85 (29.3%)	68 (26.3%)	
10 ⁷ -10 ⁹ copies/mL	125 (43.1%)	129 (49.8%)	
10^{10} - 10^{12} copies/mL	33 (11.4%)	20 (7.7%)	
Type of contact with index case, n (%)	(111.70)	20 (11170)	
Household contact	338 (28.2%)	302 (27.1%)	
Healthcare worker	130 (10.9%)	131 (11.7%)	
Nursing home worker	584 (48.7%)	550 (49.3%)	
Nursing home resident	160 (13.4%)	133 (11.9%)	
Routine use of mask, n (%)‡	100 (13.470)	155 (11.770)	
Yes	825 (68.9%)	730 (65 4%)	
No		730 (65.4%)	
	256 (21.4%)	251 (22.5%)	
NA	117 (9.7%)	135 (12.1%)	
Sleeping in the same room as the index case, n (%)	(((70 (6 000/)	
Yes	66 (5.51%)	78 (6.99%)	
No	951 (79.4%)	834 (74.7%)	
NA	181 (15.1%)	204 (18.3%)	

- * Baseline PCR result was not available for 21 participants in the control arm and 14 participants in the intervention arm.
- † Pre-screening PCR was positive at the designated hospital lab prior to enrollment, but the result was negative (undetectable $< 10^4$ copies/mL) at the research lab from the swab collected on day 1.
- ‡ Routine use of mask refers to use at the time of exposure.

428

Table 2. Outcomes of hydroxychloroquine prophylaxis against Covid-19 (intention-to-treat population).

	Control	Intervention	
	arm	arm	
	Events (%)	Events (%)	RR* (95% CI)
Primary outcome	N=1198	N=1116	
Overall $(N = 2,314)$			
PCR confirmed symptomatic Covid19	74 (6.2%)	64 (5.7%)	0.89 (0.54, 1.46)
Clinical and laboratory criteria	60 (5.0%)	49 (4.4%)	
Hospital or vital records criteria	14 (1.2%)	15 (1.3%)	
PCR (-) at baseline (N =2000)	N=1042	N=958	
PCR-confirmed symptomatic Covid19	45 (4.3%)	29 (3.0%)	1.45 (0.73, 2.88)
Clinical and laboratory criteria	37 (3.6%)	24 (2.5%)	
Hospital or vital records criteria	8 (0.8%)	5 (0.5%)	
PCR (+) at baseline (N=314)	N=156	N=158	
PCR-confirmed symptomatic Covid19	29 (18.6%)	35 (22.2%)	0.96 (0.58, 1.58)
Clinical and laboratory criteria	23 (14.7%)	25 (15.8%)	
Hospital or vital records criteria	6 (3.9%)	10 (6.3%)	
Secondary outcomes (N= 2,000) †	N=1042	N=958	
Covid19 either symptomatically			
compatible or PCR positivity	185 (17.8%)	179 (18.7%)	1.04 (0.77, 1.41)
regardless of symptoms			
Laboratory criteria ‡	67 (6.4%)	58 (6.1%)	
Clinical criteria	150 (14.4%)	144 (15.0%)	
Hospital or vital records criteria	8 (9.7%)	5 (0.5%)	
Serology positivity on day 14	91 (8.7%)	137 (14.3%)	1.6 (0.96, 2.69)
IgM positivity	70 (6.7%)	100 (10.4%)	
IgG positivity	82 (7.9%)	118 (12.3%)	

RR: Risk ratio. **CI**: confidence interval.

^{*} Risk ratios are adjusted for contact-level variables (age, gender, region, and time of exposure).

[†] Excluding PCR positive at baseline.

[‡] PCR confirmed either symptomatic or asymptomatic.

[☐] Symptoms compatible with Covid-19 regardless of PCR result

The components of the primary and secondary outcomes are not mutually exclusive.

	Control arm N=1,300	Intervention arm N=1,197	P-value
Reported full adherence to trial intervention	1,268 (97.5%)	1,138 (95.1%)	
Adverse events	1,208 (97.5%)	1,130 (73.170)	
Any AE	77 (5.9%)	671 (51.6%)	< 0.001
Cardiac disorder (palpitations)	1 (0.1%)	5 (0.4%)	<0.001
Gastrointestinal disorder (diarrhea, abdominal	1 (0.170)	3 (0.470)	
	22 (2.50/)	510 (42 60/)	
pain, and vomiting)	33 (2.5%)	510 (42.6%)	
Nervous system disorder (headache, taste	22 (2.50()	2(0 (21 70/)	
change, dizziness)	32 (2.5%)	260 (21.7%)	
General disorder (myalgia, fatigue, malaise)	10 (0.8%)	103 (8.6%)	0.001#
Intensity			<0.001*
Grade 1	44 (3.4%)	573 (44.1%)	
Grade 2	14 (1.1%)	68 (5.2%)	
Grade 3	2 (0.2%)	13 (1.0%)	
Grade 4	10 (0.8%)	11 (0.8%)	
Grade 5	7 (0.5%)	6 (0.5%)	
Serious AE †	17	14	
Hospitalization	12	11	
Deaths	8	5	
Treatment-related Serious AE	0	0	
AE of special interest (cardiac) ‡	1	5	

^{*} overall p-value for grading

[†] None of the serious adverse events (SAE) were adjudicated as related to HCQ by the pharmacovigilance consultants.

Death and hospitalization were not mutually exclusive; five deaths occurred at the hospital while other participants died at a nursing home.

[‡] Cardiac disorders were all palpitations episodes; 3 of 5 events in the intervention arm were adjudicated as possibly related to the study drug by the independent pharmacovigilance consultants. Details are provided in Table S6 (Supplementary material).





